Slide 1: APADAZ Commercial Update Call
K Pharm APADAZ® Commercial Update Call
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our prodrug product candidates, the timing of and our ability to obtain
Slide 3: Call Participants
Call Participants + Travis Mickle, Ph.D. - President & Chief Executive Officer + R. LaDuane Clifton, CPA - Chief Financial Officer, Secretary & Treasurer + Gordon K. “Rusty” Johnson — Chief Business Officer
Slide 4: Key Highlights
Key Highlights + According to estimates by Managed Markets Insights and Technologies (MMIT), branded APADAZ® has 15% unrestricted formulary access to all commercial lives + Authorized generic (benzhydrocodone/APAP, or “AG-APADAZ”) has 91% unrestricted access to all commercial lives and 90% unrestric
Slide 5: HC/APAP Market Update - 2018
HC/APAP Market Update - 2018 « Large volume, primarily generic market in 2018 + Hydrocodone/acetaminophen (HC/APAP) coverage primarily driven by Commercial and Medicare coverage 2018 Utilizatio Payor Catego (HC/APAP tabs) % of Total Commercial 1,625,304,292 41% Medicare 1,569,498,241 39% Managed Med
Slide 6: HC/APAP Market Update - 2018
HC/APAP Market Update - 2018 + Most HC/APAP volume flows through the top 6 PBM’s Utilization Volume by PBM (Top 6) ey (HC/APAP tabs) Express Scripts 412,716,705 CVS Caremark 368,923,972 OptumRx 237,666,117 Prime Therapeutics 143,341,764 Medimpact Healthcare 52,234,276 Cigna 41,026,605 Total 1,225,90
Slide 7: APADAZ Formulary Coverage - Commercial
APADAZ® Formulary Coverage - Commercial + According to MMIT estimates, branded APADAZ has 15% unrestricted access for Commercial plans, generally at a Tier 3 or equivalent status * According to MMIT estimates, AG-APADAZ has 91% unrestricted access for Commercial plans o Listed at preferred generic f
Slide 8: APADAZ Formulary Coverage - State Medicaids
APADAZ® Formulary Coverage - State Medicaids * According to MMIT estimates, AG-APADAZ has unrestricted access to 90% of state Medicaid plans with 59% in the preferred generic category * While smaller overall compared to Commercial and Medicare lives, we believe state Medicaids may represent a lower
Slide 9: APADAZ Next Steps
APADAZ® Next Steps + We believe broad formulary adoption with preferred generic status represents a key milestone to begin market conversion + Actively working with plans to “prefer” AG-APADAZ over HC/APAP + Outreach to current and previous PBM/payor leads (now on formulary with preferred generic st